PARIS--(BUSINESS WIRE)--Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, is happy to announce a series of senior leadership appointments to drive the company’s growth as it prepares for industrialization and commercial launch. The firm has appointed 5 seasoned executives to lead strategic and operational developments across all key functions, ranging from product development to regulatory and market access, finance, human resources and legal.

巴黎-（商业线）-Ganymed Robotics是整形外科医生计算机视觉软件和机器人技术的开发者，很乐意宣布一系列高级领导任命，以推动该公司的发展，为工业化和商业推出做准备。该公司已任命5名经验丰富的高管，领导所有关键职能的战略和运营发展，从产品开发到监管和市场准入，金融，人力资源和法律。

Former companies include ZimmerBiomet, Alphatec, EOS Imaging, Corwave, Beckton Dickinson, Robocath, Médecins Sans Frontières..

前公司包括ZimmerBiomet，Alphatec，EOS Imaging，Corwave，Beckton Dickinson，Robocath，无国界医生组织。。

The composition of the new Executive Committee exhibits strong expertise in both launching innovative medical devices and scaling medtech companies, as well as gender parity. It is composed of 8 members : Sophie Cahen, CEO and co-founder, Silvère Lucquin, Chief Operating Officer, and Michel Vernizeau, VP R&D, and 5 seasoned new members: Lukas Vancura as VP Product Marketing, Clémentine Liard as VP Quality Assurance and Regulatory Affairs (QARA), Sandra Demol as Human Resources Director, Julien Puaux as VP Finance and Juliette Loget as General Counsel.

新执行委员会的组成在启动创新医疗设备和扩大medtech公司规模以及性别平等方面表现出强大的专业知识。它由8名成员组成：首席运营官Sophie Cahen，首席执行官兼共同创始人SilvèreLucquin，副总裁Michel Vernizeau和5名经验丰富的新成员：Lukas Vancura担任副总裁产品营销，ClémentineLiard担任副总裁质量保证和监管事务（QARA），Sandra Demol担任人力资源总监，Julien Puaux担任副总裁财务部，Juliette Loget担任总顾问。

These additions to the Executive Committee reflect Ganymed’s continued attractiveness for talents of all seniority, and its commitment to bringing its game-changing arthroplasty robot into operating rooms as quickly as possible..

执行委员会的这些增加反映了Ganymed对所有资历人才的持续吸引力，以及其尽快将改变游戏规则的关节成形术机器人带入手术室的承诺。。

“I am delighted to partner with such talented senior executives who bring to the company their impressive experience and recognized expertise, as we accelerate the development of our revolutionary patented technology platform and prepare for industrialization and launch of our first surgical robotic assistant for knee arthroplasty,” says Sophie Cahen.

“我很高兴与这些才华横溢的高级高管合作，他们为公司带来了令人印象深刻的经验和公认的专业知识，因为我们加速了革命性专利技术平台的开发，为工业化做准备，并推出了我们第一位膝关节置换手术机器人助理，”索菲·卡恩说。

“The arrival of the leadership team’s newest members is a testimony of the swift growth that Ganymed accomplished over the past 18 months, both on the scientific and operational fronts, and speaks to a team united by a profound sense of shared purpose.”.

“领导团队最新成员的到来证明了Ganymed在过去18个月中在科学和业务方面取得的迅速增长，并与一个深刻的共同目标意识联合起来的团队交谈。”。

Ganymed Robotics’ ambition is to democratize access to quality care in hard tissue surgery. The company aims to secure and standardize a complex surgical gesture, so that each patient gets the right, personalized care. The first application is a co-manipulated surgical robotic assistant for total knee arthroplasty (TKA).

Ganymed机器人公司的目标是使硬组织手术中优质护理的普及。该公司旨在确保和标准化复杂的手术手势，以便每位患者都能获得正确的个性化护理。第一个应用是用于全膝关节置换术（TKA）的共同操作的手术机器人助手。

It has developed a proprietary technology platform built around two disruptive innovations: contactless localization of the bones and human-machine collaborative movement..

它开发了一个专有技术平台，该平台围绕两项颠覆性创新构建：骨骼的非接触式本地化和人机协作运动。。

Over the past 18 months, Ganymed reached several major milestones, attesting of its ability to efficiently implement its growth strategy: it completed a 36 M€ Series B fundraising round with a high-profile group of healthcare investors, welcomed two world renowned independent members on its Board of Directors, Michel Therin et Mike Lobinsky, doubled the size of its team across all functions to reach 40 persons today, secured strategic partnerships, moved forward with regulatory and marketing developments, won new national and international innovation awards, and ran successful pre-clinical tests.

在过去的18个月中，Ganymed达到了几个主要里程碑，证明了其有效实施其增长战略的能力：它与知名的医疗投资者一起完成了3600万欧元的B系列筹款轮，欢迎两位世界知名的独立成员董事会，Michel Therin和Mike Lobinsky，其团队在所有职能领域的规模翻了一番，今天达到40人，获得了战略伙伴关系，推动了监管和营销发展，赢得了新的国家和国际创新奖，并成功进行了临床前测试。

With the arrival of high-profile senior executives on its leadership team, Ganymed is ideally positioned to successfully accelerate the execution of its strategic, industrial, and operational development plan..

随着高层高级管理人员到达其领导团队，Ganymed处于成功加速其战略，工业和运营发展计划执行的理想位置。。

About Ganymed Robotics

关于Ganymed机器人

Ganymed Robotics is a medical device company founded in 2018, developing the next generation of robotic assistance technologies for orthopedic surgery. The company’s mission is to improve patient outcome, surgeon experience, and overall efficiency of care delivery for its target indications. Based in Paris, Ganymed Robotics currently employs 40 people who develop a proprietary technology platform combining computer vision, a branch of artificial intelligence, and mechatronics, in close collaboration with world-class clinicians and advisors.

Ganymed Robotics是一家成立于2018年的医疗器械公司，为整形外科开发下一代机器人辅助技术。该公司的使命是改善患者的预后，外科医生的经验以及针对其目标适应症的整体护理效率。总部设在巴黎的Ganymed机器人公司目前雇用40人，与世界一流的临床医生和顾问密切合作，开发结合计算机视觉，人工智能分支和机电一体化的专有技术平台。

The first application is a robotic surgical assistant for knee arthroplasties, a common and fast-growing intervention associated with high dissatisfaction rates of above 20%. Ganymed Robotics intends to progressively deploy its technology to address several other orthopedics indications. Ganymed Robotics won national and international innovation awards, such as I-Nov, I-Lab, French Tech DeepNum20, French Tech Emergence, Deep Tech Pioneer, EIT Health, Wilco, EIC Accelerator.

第一个应用是用于膝关节置换术的机器人手术助手，这是一种常见且快速增长的干预措施，与20%以上的高不满意率相关。Ganymed机器人公司打算逐步部署其技术来解决其他一些骨科适应症。Ganymed机器人获得了国家和国际创新奖，如I-Nov，I-Lab，法国技术DeepNum20，法国技术出现，深技术先驱，EIT Health，Wilco，EIC加速器。

For more information: www.ganymedrobotics.com.

欲了解更多信息：www.ganymedrobotics.com。